Precision medicines addressing unique diseases are poised to become more accessible

unnamed file
Credit: University of Chicago Press

Today, companies are developing new models to lower the costs of manufacturing and bring [precision medicine] drugs to more patients. Among them are companies developing new business models and services, innovative equipment for on-site manufacturing in hospitals, and improved formulation technology.

Orgenesis is among the companies turning to localization to deliver precision medicines to patients… The company’s Cell & Gene Therapy Biotech Platform incorporates the following elements: POCare Therapeutics, a pipeline of licensed cell and gene therapies (CGTs); POCare Technologies, a suite of proprietary and in-licensed technologies; and POCare Network, a collaborative, international ecosystem of research institutes and hospitals. This platform, the company asserts, is about decentralization, enabling precision medicines to be prepared on-site at hospitals.

Related article:  Good news for a coronavirus vaccine: Human immune system offers robust response, study shows

The platform automates the production of precision medicines by validating “closed box” processes to reduce cleanroom footprints once the product gets to market. [CEO Vered] Caplan works to develop and commercialize drugs that can be licensed for use by hospitals in the Orgenesis network.


“What we do is offer a low-cost supply platform with processing and regulatory solutions that are validated in a harmonized fashion,” she details. “Essentially, we take responsibility for R&D. Our hospitals are partners, and because we’re working in a network, the economic burden isn’t high, and we can supply the therapy at a reasonable cost.”

Read the original post

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend